JPRN-UMIN000002176已完成2 期
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01) - Radiation therapy with S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)
PerSeUS-GP0 个研究点目标入组 40 人开始时间: 2009年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Lung fibrosis or interstitial pneumonia. (should be confirmed by chest radiograph or CT within 28 days before the entry) 2. Watery diarrhea or chronic diarrhea 3. Regular use of Fenitoin, Warfarin or Frucitocin. 4. Pleural effusion or ascites. 5. Active infection. 6. Other malignancies. 7. Active gastroduodenal ulcer. 8. Serious comorbid illness. (heart failure, renal failure, liver failure, intestinal paralysis, uncontrolled diabetes, etc) 9. Serious mental disorder. 10. Serious drug allergy. 11. During pregnancy or lactation. 12. Patients who were judged inappropriate for the entry to this study by the investigators.
研究者
相似试验
招募中
2 期
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02)ocally advanced pancreatic cancerJPRN-UMIN000010435PerSeUS: Perpetual Study estimated-by United Sections in gifu40
招募中
不适用
A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinomapancreatic cancerJPRN-UMIN000035232Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University50
尚未招募
1 期
A phase II clinical trial of neoadjyvant chemoradiation therapy using Gemcitabine combined with IMRT for borderline resectable pancreatic cancerborderline resectable pancreatic cancerJPRN-UMIN000010113Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity37
尚未招募
不适用
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamideHER2 negative primary breast cancerJPRN-UMIN000019787Dept of breast oncology50
进行中（未招募）
不适用
Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem MammakarzinomeEUCTR2007-000924-42-DESana Klinikum Lichtenberg